Cercek A, Boerner T, Tan BR, et al. - Researchers examined clinical outcomes of patients with unresectable intrahepatic cholangiocarcinoma following hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin. They performed a single-arm, phase 2 clinical trial including 38 patients with unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin. An objective radiographic response was reported in 58% of the patients and disease control was achieved in 84%. Median overall survival of 25.0 months was observed, and sufficient response to undergo resection was achieved in 4 patients; no association of lymph node status with clinical benefit was observed. These findings support the clinical activity of combination hepatic arterial infusion floxuridine with systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma.